Scilex (SCLX) Competitors

Scilex (NASDAQ:SCLX) and I-Mab (NASDAQ:IMAB) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, media sentiment, analyst recommendations, risk and dividends.

Is SCLX or IMAB more profitable?

I-Mab has a net margin of 0.00% compared to Scilex's net margin of -146.93%. Scilex's return on equity of 0.00% beat I-Mab's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scilex	-146.93%	N/A	-82.65%
I-Mab	N/A	-19.81%	-18.63%

Do institutionals & insiders have more ownership in SCLX or IMAB?

69.7% of Scilex shares are held by institutional investors. Comparatively, 38.4% of I-Mab shares are held by institutional investors. 7.9% of Scilex shares are held by insiders. Comparatively, 22.1% of I-Mab shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Do analysts prefer SCLX or IMAB?

Scilex presently has a consensus price target of $455.00, suggesting a potential upside of 3,704.35%. I-Mab has a consensus price target of $6.00, suggesting a potential upside of 184.36%. Given Scilex's higher probable upside, research analysts plainly believe Scilex is more favorable than I-Mab.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scilex	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50
I-Mab	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.33

Does the media favor SCLX or IMAB?

In the previous week, I-Mab had 1 more articles in the media than Scilex. MarketBeat recorded 3 mentions for I-Mab and 2 mentions for Scilex. Scilex's average media sentiment score of 0.93 beat I-Mab's score of 0.46 indicating that Scilex is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scilex	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
I-Mab	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has better earnings and valuation, SCLX or IMAB?

I-Mab has lower revenue, but higher earnings than Scilex.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scilex	$56.59M	1.47	-$72.81M	-$29.02	-0.41
I-Mab	N/A	N/A	-$22.23M	N/A	N/A

Which has more risk and volatility, SCLX or IMAB?

Scilex has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500. Comparatively, I-Mab has a beta of 1.4, meaning that its share price is 40% more volatile than the S&P 500.

Summary

I-Mab beats Scilex on 8 of the 13 factors compared between the two stocks.